NCT02824133View on ClinicalTrials.gov

"Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

October 31, 2018

Conditions
Recurrent IDHwt Gliomas With FGFR3-TACC3 FusionRecurrent IDHwt Gliomas With FGFR1-TACC1 Fusion
Interventions
DRUG

AZD4547

80 mg bd (per os)

Trial Locations (1)

75013

Neuro onsology unit - Groupe Hospitalier Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02824133 - "Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" | Biotech Hunter | Biotech Hunter